Form 4: Guardant Health Director Reports RSU Vesting and Share Sale

Guardant Health Director Myrtle S. Potter reported the vesting of 68 restricted stock units and the subsequent sale of 26 common shares under a Rule 10b5-1 plan.

Summary

• Myrtle S. Potter, a Director of Guardant Health, Inc., reported transactions involving the company's common stock and restricted stock units (RSUs).
• On September 15, 2025, 68 restricted stock units vested, resulting in the acquisition of 68 shares of common stock at a price of $0.
• On September 17, 2025, 26 shares of common stock were sold at a price of $55.63 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-arranged schedule for the purchase or sale of equity securities.
• Following these transactions, Myrtle S. Potter beneficially owns 18,281 shares of common stock and 69 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and a small share sale) under a 10b5-1 plan, which is neutral in sentiment. It does not indicate significant positive or negative developments for the company.

Positives

• The vesting of 68 restricted stock units indicates continued compensation for the director.
• The transactions were executed under a Rule 10b5-1 plan, suggesting pre-planned and automated trading, which can reduce concerns about opportunistic insider trading.

Negatives

• The sale of 26 common shares by a director, though a small amount, represents a reduction in direct ownership.

Future Outlook

The remaining 69 restricted stock units are scheduled to vest in substantially equal installments on each monthly anniversary of October 15, 2022, with the final vesting expected by October 15, 2025.

Industry Context

This filing represents a routine insider transaction for a director of a publicly traded healthcare company, common across various industries for executive compensation and personal financial management.

Related Party Transactions

• Myrtle S. Potter, a Director of Guardant Health, Inc., engaged in transactions involving the company's equity, specifically the vesting of restricted stock units and the sale of common stock. These are considered related party transactions as they involve an insider of the company.

Stakeholder Impact

• Shareholders: Minor impact due to a small insider share sale, potentially viewed as routine under a 10b5-1 plan. No significant impact on company valuation or strategic direction is implied by these transactions.

Next Steps

• Final vesting of the remaining 69 restricted stock units is expected by October 15, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (RSU vesting and a small share sale under a 10b5-1 plan) by a director. Such transactions are generally not indicative of significant changes in the company's fundamental outlook or performance. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation based solely on this filing.

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Myrtle S. Potter, Director, Restricted Stock Units, RSU Vesting, Share Sale, 10b5-1 Plan